Literature DB >> 16571199

Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review.

Pirjo Räsänen1, Eija Roine, Harri Sintonen, Virpi Semberg-Konttinen, Olli-Pekka Ryynänen, Risto Roine.   

Abstract

OBJECTIVES: The objectives of this study were to identify, in a systematic literature review, published studies having used quality-adjusted life years (QALYs) based on actual measurements of patients' health-related quality of life (HRQoL) and to determine which HRQoL instruments have been used to calculate QALYs. Furthermore, the aims were to characterize studies with regard to medical specialty, intervention studied, results obtained, quality, country of origin, QALY gain observed, and interpretation of results regarding cost-effectiveness.
METHODS: Systematic searches of the literature were made using the MEDLINE, Embase, CINAHL, SCI, and Cochrane Library electronic databases. Initial screening of identified articles was based on abstracts read independently by two of the authors; full-text articles were again evaluated by two authors, who made the final decision on which articles should be included.
RESULTS: The search identified 3,882 articles; 624 were obtained for closer review. Of the reviewed full-text articles, seventy reported QALYs based on actual before-after measurements using a valid HRQoL instrument. The most frequently used instrument was EuroQol HRQoL instrument (EQ-5D, 47.5 percent). Other instruments used were Health Utilities Index (HUI, 8.8 percent), the Rosser-Kind Index (6.3 percent), Quality of Well-Being (QWB, 6.3 percent), Short Form-6D (SF-6D, 5.0 percent), and 15D (2.5 percent). The rest (23.8 percent) used a direct valuation method: Time Trade-Off (10.0 percent), Standard Gamble (5.0 percent), visual analogue scale (5.0 percent), or rating scale (3.8 percent). The most frequently studied medical specialties were orthopedics (15.5 percent), pulmonary diseases (12.7 percent), and cardiology (9.9 percent). Ninety percent of the studies came from four countries: United Kingdom, United States, Canada, the Netherlands. Approximately half of the papers were methodologically high quality randomized trials. Forty-nine percent of the studied interventions were viewed by the authors of the original studies as being cost-effective; only 13 percent of interventions were deemed not to be cost-effective.
CONCLUSIONS: Although QALYs gained are considered an important measure of effectiveness of health care, the number of studies in which QALYs are based on actual measurements of patients' HRQoL is still fairly limited.

Entities:  

Mesh:

Year:  2006        PMID: 16571199     DOI: 10.1017/S0266462306051051

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  91 in total

1.  Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure.

Authors:  Taru Kantola; Suvi Mäklin; Anna-Maria Koivusalo; Pirjo Räsänen; Anne Rissanen; Risto Roine; Harri Sintonen; Krister Höckerstedt; Helena Isoniemi
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.

Authors:  Nick Kontodimopoulos
Journal:  Qual Life Res       Date:  2014-11-13       Impact factor: 4.147

3.  The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries.

Authors:  Raymond Oppong; Billingsley Kaambwa; Jacqueline Nuttall; Kerenza Hood; Richard D Smith; Joanna Coast
Journal:  Eur J Health Econ       Date:  2011-11-05

4.  Time trade-off and attitudes toward euthanasia: implications of using 'death' as an anchor in health state valuation.

Authors:  Liv A Augestad; Kim Rand-Hendriksen; Knut Stavem; Ivar Sønbø Kristiansen
Journal:  Qual Life Res       Date:  2012-06-08       Impact factor: 4.147

Review 5.  Evaluation of content on EQ-5D as compared to disease-specific utility measures.

Authors:  Fang-Ju Lin; Louise Longworth; A Simon Pickard
Journal:  Qual Life Res       Date:  2012-06-23       Impact factor: 4.147

6.  Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.

Authors:  K Lien; V C Tam; Y J Ko; N Mittmann; M C Cheung; K K W Chan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

7.  Socio-demographic, clinical characteristics and utilization of mental health care services associated with SF-6D utility scores in patients with mental disorders: contributions of the quantile regression.

Authors:  Amélie Prigent; Blaise Kamendje-Tchokobou; Karine Chevreul
Journal:  Qual Life Res       Date:  2017-06-21       Impact factor: 4.147

8.  Chilean population norms derived from the health-related quality of Life SF-6D.

Authors:  Miguel A Garcia-Gordillo; Daniel Collado-Mateo; Pedro R Olivares; José C Adsuar
Journal:  Eur J Health Econ       Date:  2017-06-19

9.  Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina.

Authors:  Federico Augustovski; Martín Chaparro; Alfredo Palacios; Lizheng Shi; Andrea Beratarrechea; Vilma Irazola; Adolfo Rubinstein; Katherine Mills; Jiang He; Andrés Pichon Riviere
Journal:  Value Health       Date:  2018-08-30       Impact factor: 5.725

10.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.